Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ketobemidone
- Development stage
- Phase 4
- Modality
- Small Molecules
- Administration
- Oral, Intravenous, Intramuscular, Subcutaneous, Rectal
01
Overview
Ketobemidone is a powerful synthetic opioid analgesic of the phenylpiperidine class, used primarily for the management of severe pain. Its analgesic potency is comparable to morphine. In addition to its action as an agonist at mu-, kappa-, and delta-opioid receptors, it also exhibits N-methyl-D-aspartate (NMDA) receptor antagonist properties, which may contribute to its effectiveness in certain types of pain that are resistant to other opioids. The drug undergoes hepatic metabolism mainly via glucuronidation and N-demethylation pathways, with possible involvement of CYP3A4 enzymes. It is marketed in several Scandinavian countries for severe pain but has been withdrawn from some markets such as Sweden[1][2][3][5].
- Brand names
- KetoganCliradonCymidonKetorax
- Other names
- ketobemidone hydrochloride1-(4-(m-hydroxyphenyl)-1-methyl-4-piperidyl)-1-propanone
02
Targets
DOR (Opioid Receptor Delta 1)KOR (Kappa opioid receptor)MOR (Mu opioid receptor)NMDAR (Glutamate receptor ionotropic, NMDA)
Beyond the preview
Go deeper on ketobemidone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ketobemidone.